Drugs / B7-H3CART
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07509034 | Oct 2026 → Jan 2030 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT06646627 | Nov 2024 → Jan 2027 expected | ovarian cancer | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT06500819 | Jul 2024 → Jul 2029 expected | neuroblastoma, osteosarcoma | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT04385173 | Dec 2022 → Mar 2024 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05474378 | Jul 2022 → Feb 2027 expected | nervous system disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04077866 | Jun 2023 → Jun 2025 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7-H3 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509034 ↗ |
| Action | Deplete | “can specifically attack patient glioblastoma cells that expressing B7-H3.” NCT04385173 ↗ |
| Modality | Cell therapy | “B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells” NCT04077866 ↗ |
| Route | Other | “via intratumoral or intracerebroventricular injection” NCT04077866 ↗ |
| Target | CD276 | “Chimeric antigen receptor (CAR) T cells recognize and kill target-expressing tumor cells. * B7 homolog 3 (B7-H3, also known as CD276) is a surface molecule highly expressed in...” NCT07509034 ↗ |